Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Licensing Revenues to Date YEAR PRODUCT INDICATION PARTNER DEAL TYPE SIGN-UP FEE MILESTONES SERVICES TOTAL 2001-2007 DK-1001-01 Idiopathic Pulmonary Fibrosis Intermune Inc. Asset sale CHF 100'000 CHF 2'000'000 - CHF 2'100'000 2006-2009 DK-1000-01 Pulmonary Arterial Hypertension Biogen Idec Inc. Licensing and Collaboration Agreement CHF 9'750'000 - CHF 33'970'000 CHF 43'720'000 2008-2011 DK-0138-01 MRSA in Cystic Fibrosis LungRx LLC Licensing and Collaboration Agreement CHF 100'000 - - CHF 100'000 2010-2011 DK-1000-01 Pulmonary Arterial Hypertension 2010-2011 DK-1000-02 DK-1000-03 DK-1000-04 Sarcoidosis Idiopathic Pulmonary Fibrosis Acute Respiratory Distress Syndrome LungRx LLC and Biogen Idec Inc. Licensing and Collaboration Agreement - - CHF 386'000 CHF 386'000 LungRx LLC Licensing and Collaboration Agreement - - - - TOTAL REVENUES CHF 46'306'000 Lung Rx, a wholly-owned subsidiary of United Therapeutics (Nasdaq: UTHR), has acquired the Aviptadil platform in January 2010 and returned it to mondoBIOTECH on May 2011 due to strategic reasons 52
Licensed Products • Aviptadil platform to Lung Rx LLC, wholly owned subsidiary of United Therapeutics Corp. – UTHR (from Biogen Idec Inc.) Indication: Pulmonary Arterial Hypertension (PAH) Milestones: US$ 10m end of phase III; US$ 20m marketing authorization Royalties: approx. 10% on net sales on the whole platform Status: Clinical POC/Phase IIa Indications: respectively Sarcoidosis, Idiopathic Interstitial Pneumonia (IIP-IPF) and Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) Milestones: US$ 10m end of phase III; US$ 10m marketing authorization Royalties: approx. 10% on net sales on the whole platform Status: Clinical POC Biogen Idec in-licensed the IP rights on the platform in 2006. In February 2010, with the agreement of Biogen Idec, the platform was licensed to Lung Rx, with Biogen Idec remaining financially involved for the PAH indication. Both companies focused on the development of Aviptadil only for the disease which was their major interest, i.e. PAH. In May 2011, Lung Rx for strategic reasons returned to mondoBIOTECH and all IP rights, know-how and ownership of data of the Aviptadil Platform. The data of the double- blind multinational Phase II study performed on PAH suggested that Aviptadil may be promisingly re-directed for already identified acute indications and delivered to patients via a more suitable formulation and route of administration. Based on such data and on internal know-how on Aviptadil, we intend to start Phase II development for Aviptadil in ARDS/ALI together with our Community. 53
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51: Products licensed DasKloster 1001-0
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?